View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 28, 2021

Ampio begins Phase II dosing for Covid-related respiratory distress

The study will assess the efficacy of Ampion for treating patients suffering from Covid-19-related respiratory distress.

Ampio Pharmaceuticals has started the randomisation and dosing of patients for its AP-019 Phase II clinical trial against long Covid.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The double-blind, placebo-controlled trial will assess the efficacy of inhaled Ampion for treating respiratory distress due to Covid-19.

The biopharmaceutical company initiated the Phase II study following positive results from its AP-014 Phase I trial.

The final results of the Phase I trial indicated that Ampion led to a 78% decrease in all-cause mortality in patients suffering from COVID-19 respiratory distress compared to the standard of care (SOC).

Ampion is a novel biologic drug containing a blood-derived cyclized peptide and small molecules that work together to address a variety of inflammatory conditions.

The agent is being investigated for treating inflammation in the lungs of Covid-19 patients.

Ampio president and CEO Michael Macaluso said: “We saw strong, positive results in our Phase I trial, reducing all-cause mortality in Covid-19 respiratory distress by 78%.

“If this Phase II study further confirms the efficacy results seen in our Phase I study, I can envision moving forward quickly with an application for Emergency Use Authorization for Ampion in treating patients suffering from respiratory distress due to Covid-19.”

The Phase II study will be conducted at multiple centres.

Ampio has also secured US Food and Drug Administration (FDA) approval to expand the AP-019 study to India.

India witnessed a sharp surge in Covid-19 cases earlier this year. It is the second worst affected country in terms of the total number of confirmed Covid cases.

Macaluso added: “Roughly 300 people per day are dying of Covid-19 in the US, with a seven-day average of 10,000 per day worldwide.

“There is a perception the vaccine rollout has ended the pandemic, but Covid-19 is likely to remain a concern for some time to come, and physicians need tools to treat it.”

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena